Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.43 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179861 | 0.88 | AR (0.64) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4168825 | 0.84 | AR (1.00) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4175005 | 0.84 | AR (0.56) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4182930 | 0.83 | AR (0.62) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4188051 | 0.81 | AR (0.56) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4171609 | 0.79 | AR (0.70) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL8550179 | 0.79 | AR (0.60) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL13875515 | 0.79 | AR (0.57) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4181543 | 0.78 | AR (0.73) | ARSLC6A4KCNH2SLC6A3MRGPRX4 | |
| SCHEMBL4188134 | 0.78 | AR (0.73) | ARSLC6A4KCNH2SLC6A3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885SLC6A4 1384/4885KCNH2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.